@nunopadrao.bsky.social
Reposted
new News & Views out in Nature
www.nature.com/articles/d41... on last week's www.nature.com/articles/s41...
www.nature.com/articles/d41... on last week's www.nature.com/articles/s41...
How fasting boosts breast cancer therapy
A discovery in mice reveals why fasting enhances a type of breast cancer treatment — a hormone-signalling pathway and gene-expression changes have key roles.
www.nature.com
December 18, 2025 at 8:26 AM
new News & Views out in Nature
www.nature.com/articles/d41... on last week's www.nature.com/articles/s41...
www.nature.com/articles/d41... on last week's www.nature.com/articles/s41...
Reposted
Therapies to mimic the metabolic effects of fasting might improve the effectiveness of hormone treatments for breast cancer, according to a study in Nature. The research finds that the metabolites associated with fasting can boost anti-tumour properties involved in some cellular pathways. #medsky 🧪
Fasting boosts breast cancer therapy efficacy via glucocorticoid activation - Nature
Beneficial effects of fasting combined with endocrine therapy for oestrogen receptor-α-expressing breast cancers can be recapitulated using exogenous glucocorticoid receptor ligands instead of fasting to reduce harmful effects.
go.nature.com
December 11, 2025 at 2:51 PM
Therapies to mimic the metabolic effects of fasting might improve the effectiveness of hormone treatments for breast cancer, according to a study in Nature. The research finds that the metabolites associated with fasting can boost anti-tumour properties involved in some cellular pathways. #medsky 🧪
Reposted
Corticosteroids may re-sensitize metastatic HR+ breast cancer to endocrine therapy by mimicking cortisol-driven fasting responses. Our study, published in Nature, shows a potential new use for a cheap and widely used drug class. ➡️ www.nki.nl/news-events/...
December 10, 2025 at 4:30 PM
Corticosteroids may re-sensitize metastatic HR+ breast cancer to endocrine therapy by mimicking cortisol-driven fasting responses. Our study, published in Nature, shows a potential new use for a cheap and widely used drug class. ➡️ www.nki.nl/news-events/...
Very happy to see one of my PhD stories out in @pnas.org!! 🚀🚀
We find that targeting TRIM24 proves to be a valuable alternative to disrupt ER activity in therapy-resistant breast cancer! 💪🏻💪🏻
Thanks to @zwartlab.bsky.social, the co-authors and the TRIM-NET consortium!
www.pnas.org/doi/10.1073/...
We find that targeting TRIM24 proves to be a valuable alternative to disrupt ER activity in therapy-resistant breast cancer! 💪🏻💪🏻
Thanks to @zwartlab.bsky.social, the co-authors and the TRIM-NET consortium!
www.pnas.org/doi/10.1073/...
TRIM24 as a therapeutic target in endocrine treatment–resistant breast cancer | PNAS
While Estrogen receptor alpha (ERα)+ breast cancer treatment is considered effective,
resistance to endocrine therapy is common. Since ERα is still...
www.pnas.org
August 16, 2025 at 3:28 PM
Very happy to see one of my PhD stories out in @pnas.org!! 🚀🚀
We find that targeting TRIM24 proves to be a valuable alternative to disrupt ER activity in therapy-resistant breast cancer! 💪🏻💪🏻
Thanks to @zwartlab.bsky.social, the co-authors and the TRIM-NET consortium!
www.pnas.org/doi/10.1073/...
We find that targeting TRIM24 proves to be a valuable alternative to disrupt ER activity in therapy-resistant breast cancer! 💪🏻💪🏻
Thanks to @zwartlab.bsky.social, the co-authors and the TRIM-NET consortium!
www.pnas.org/doi/10.1073/...